Join us as Josh Apgar, PhD, Co-founder and CSO of Applied BioMath, walks through two case studies showing how Applied BioMath Assess™ can be used early in drug R&D to gain insight into project feasibility. You can attend either webinar or both. The content is not dependent on each other.
Introductory Example | Parameterize and Benchmark an anti-PD-L1 Model
November 14, 2023 from 12-1pm ET
- Set up a model using data on PD-L1/PD1
- Benchmarked the model using PK data for atezolizumab
- Predicted clinical doses and determined parameters that drive that dose
More Complex Design Considerations | Make a Best in Class Bispecific Drug
November 16, 2023 from 12-1pm ET
- Set up a model using data on PD1 and CTLA4
- Benchmarked the model using PK/PD data for Lorigerlimab
- Identified best in class parameters for a PD1/CTLA4
About Applied BioMath Assess™
Applying model-informed drug discovery and development (MID3) early in development can reduce late-stage risk by determining feasibility of drugging a given target, prioritizing between targets, or defining optimal drug properties for a target product profile. However, the lack of pharmacokinetic (PK) and pharmacodynamic (PD) data available at early stages can make modeling a challenge. For this reason, we developed Early Feasibility Assessment (EFA): a method for making effective dose predictions using mechanistic PK/PD models built from general biophysical principles and parameterized by data that is readily available early in drug discovery.
Applied BioMath Assess™ is a point-and-click, MID3 software for performing EFA across various modalities.